- ADHERE was largest and most innovative clinical trial of CIDP patients to date
- VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action
- VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-approved to treat CIDP
Argenx's ADHERE Study Published In The Lancet Neurology, Showcasing VYVGART Hytrulo's Impact On Reducing CIDP Relapse And Disease Progression
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.